Baird Capital Announces Sale of Hopebridge, Retains Minority Stake

Baird Capital

CHICAGO – May 8, 2019 – Baird Capital, the direct private investment arm of Baird, recently announced the sale of Hopebridge LLC (Hopebridge) to Arsenal Capital Partners. Baird Capital will retain a minority stake in the company. The financial terms of the deal were not disclosed.

Headquartered in Indianapolis, Hopebridge was founded in 2005 to serve the growing need for autism treatment services and to improve the lives of affected children and families. The company is committed to providing personalized outpatient ABA, occupational, speech, and feeding therapies for children touched by autism spectrum disorder and behavioral, physical, social, communication and sensory challenges. Hopebridge continues to open state-of-the-art autism therapy centers in new communities to reach patients and families who need services. With locations in Georgia, Indiana, Kentucky and Ohio, Hopebridge expects to operate 41 centers by June 2019, compared to 14 at the time of Baird’s initial 2017 investment.

“Baird Capital is fortunate to have worked with Hopebridge and its talented leadership team, and we are pleased to continue supporting the company’s future growth,” said Mike Bernstein, Partner, Baird Capital.

About Baird Capital
Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 300 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. Incorporated. For more information, please visit BairdCapital.com.

For additional information, contact:
Baird Public Relations 
414-765-7250

Categories: News

Tags:

Antares and Bain Capital Credit Support Frazier Healthcare Partners’ Acquisition of Comprehensive Pharmacy Services

BainCapital

CHICAGO AND BOSTON, May 6, 2019 – The Antares Bain Capital Complete Financing Solution (ABCS), a joint venture between Antares and Bain Capital Credit, today announced the closing of a $270 million senior secured unitranche credit facility to support the acquisition of Comprehensive Pharmacy Services (“CPS”) by Frazier Healthcare Partners.

Founded in 1971 and employing over 2,500 clinical, regulatory, and operational pharmacy professionals, Comprehensive Pharmacy Services provides pharmacy support services to more than 700 hospitals and healthcare facilities across the U.S. and Puerto Rico.

“We appreciated the certainty and efficiency of the Antares and Bain Capital unitranche solution,” said Ben Magnano, general partner at Frazier Healthcare Partners.  “The Antares and Bain Capital Credit teams understand the complexities of the pharmacy space well and together delivered an optimal financing solution.”

“Antares is pleased to support Frazier Healthcare Partners and the continued growth of CPS, a trusted partner to pharmacy leaders,” said Benjamin Chapin, managing director with Antares.  “Through their use of data driven insights, fast reporting and real-time information they are distinct in their ability to deliver efficiencies and reduce costs for hospital customers.”

“Leveraging our deep sector expertise, we were able to add value and deliver a flexible financing solution that will allow Frazier Healthcare Partners to build on CPS’ strong market leadership position,” said Carolyn Hastings, a managing director at Bain Capital Credit.  “We are pleased to be supporting Frazier and look forward to a lasting collaboration as they support the company’s ongoing growth initiatives.”

ABCS provides private equity sponsors and borrowers with access to first lien unitranche loans of up to $350 million in a single transaction. Without the requirement of agency meetings or a syndication process, the Antares and Bain Capital unitranche offering delivers capital with speed and certainty.

About Antares 
With approximately $24 billion of capital under management and administration as of December 31, 2018, Antares is a private debt credit manager and leading provider of financing solutions for middle-market private equity-backed transactions. In 2018, Antares issued nearly $25 billion in financing commitments to borrowers through its robust suite of products including first lien revolvers, term loans and delayed draw term loans, 2nd lien term loans, unitranche facilities and equity investments. Antares world-class capital markets experts hold relationships with over 400 banks and institutional investors allowing the firm to structure, distribute and trade syndicated loans on behalf of its customers. Since its founding in 1996, Antares has been recognized by industry organizations as a leading provider of middle market private debt, most recently being named the 2018 Lender of the Year by ACG New York. The company maintains offices in Atlanta, Chicago, Los Angeles, New York and Toronto. Visit Antares at www.antares.com or follow the company on Twitter at www.twitter.com/antarescapital. Antares Capital is a subsidiary of Antares Holdings LP., collectively (“Antares”).

About Bain Capital Credit
Bain Capital Credit (www.baincapitalcredit.com) is a leading global credit specialist with approximately $41 billion in assets under management. Bain Capital Credit invests up and down the capital structure and across the spectrum of credit strategies, including leveraged loans, high-yield bonds, distressed debt, private lending, structured products, non-performing loans and equities. Our team of more than 200 professionals creates value through rigorous, independent analysis of thousands of corporate issuers around the world. In addition to credit, Bain Capital invests across asset classes including private equity, public equity and venture capital, and leverages the firm’s shared platform to capture opportunities in strategic areas of focus. Bain Capital Credit’s dedicated Private Credit Group focuses on providing complete financing solutions to businesses with EBITDA between $10 million and $100 million located in North America, Europe and Asia Pacific. Our dedicated global team affords us the ability to diligence the most complex situations and provide private capital to those companies.

Categories: News

Tags:

Apax Funds, CPPIB and PSP Investments agree to sell Acelity and its KCI Subsidiaries to 3M for $6.725 Billion

Apax

KCI is a leading global medical technology company focused on advanced wound care and specialty surgical applications. 

SAN ANTONIO and NEW YORK, May 2, 2019: A consortium comprised of funds advised by Apax Partners (the “Apax Funds”), together with Canada Pension Plan Investment Board (“CPPIB”) and the Public Sector Pension Investment Board (“PSP Investments”), today announced that it has entered into a definitive agreement to sell Acelity, Inc. and its KCI subsidiaries worldwide to 3M for approximately $6.725 billion. KCI markets a broad range of negative pressure wound therapy, specialty surgical and advanced wound dressing products in approximately 90 countries.

Since 2011, Apax Partners, CPPIB and PSP Investments worked closely with Acelity/KCI’s senior leadership team to transform the business into a leading global company focused on advanced wound care and specialty surgical solutions. The company’s strategic M&A program included targeted acquisitions, such as Systagenix, in 2013, and Crawford Healthcare, in 2018, and disposals of non-core businesses, such as the LifeCell business unit, which was sold for $2.9 billion in 2017, and the Therapeutic Support Systems (TSS) unit, which was sold in 2012. The company also has undertaken a range of organic growth initiatives including investments in R&D, clinical studies, and the expansion of its sales force.

The product offering includes the KCI-branded negative pressure wound therapy, advanced wound dressings, and negative pressure surgical incision management systems. The company’s industry-leading brands include V.A.C.® Therapy, PREVENA™ Therapy and PROMOGRAN PRISMA™ Matrix, as well as the iOn Digital Health platforms. Upon completion of the transaction, KCI will become an integral part of 3M’s Medical Solutions business, which applies 3M’s science to deliver safe and effective solutions that improve clinical outcomes and healthcare economics.

“Today, KCI embarks upon a new era in its long history as a pioneer in healthcare,” said R. Andrew Eckert, CEO of Acelity. “The combination of KCI with 3M will accelerate the reach of a business that is a leader in innovation, customer experience and clinical and economic evidence. Backed by the resources and expertise of 3M,KCIwill be able to offer clinicians and patients even more compelling solutions designed to speed healing and improve outcomes. I would like to thank Apax, CPPIB and PSP Investments for their close partnership and strategic direction over the years shaping KCI into a premier global advanced wound care company.”

Steven Dyson, Chairman of the Board of Acelity and Partner at Apax Partners, said, “We are proud of our close work with management to successfully transform KCI through a range of growth initiatives, including an M&A program, that enhanced the Company’s strategic direction. We believe the business will have a great future with 3M. Lastly, we are grateful for the opportunity to have joined in this highly successful investment with CPPIB and PSP, two long-standing investors in the Apax Funds.”

“CPPIB is pleased to have supported KCI’s delivery of medical devices and products that benefit millions of patients around the world. During our investment, the company helped restore lives with the launch of innovative solutions and expansion into new geographies,” said Ryan Selwood, Managing Director, Head of Direct Private Equity, CPPIB.

“We are proud to have supported KCI and its management team during its exciting transformation journey, in partnership with Apax and CPPIB,” said Simon Marc, Managing Director and Head of Private Equity, PSP Investments. “KCI has successfully invested into novel organic growth initiatives and we are confident about its continued growth prospects with 3M.”

The transaction will be effected through the sale of Acelity, Inc., a direct wholly-owned subsidiary of Acelity L.P. Inc., and is expected to close in the second half of 2019, subject to customary closing conditions and regulatory approvals.

JP Morgan and Goldman Sachs are acting as financial advisors to the consortium. Simpson Thacher & Bartlett LLP and Jackson Walker LLP are acting as legal advisors to the consortium.

About KCI, an Acelity Company
KCI, an Acelity Company, is a well trusted brand in advanced wound care. We are a leader in negative pressure wound therapy, providing solutions for both wound healing and surgical management. Our product offerings are available in more than 90 countries and deliver value through solutions that speed healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing.  Headquartered in San Antonio, Texas, KCI employs approximately 4,500 people worldwide.

About Apax Partners
Apax Partners is a leading global private equity advisory firm. Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of over c.$50 billion. The Apax Funds invest in companies across four global sectors of Healthcare, Tech & Telco, Services, and Consumer. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see: www.apax.com.

In Healthcare, the Apax Funds have invested c.$8 billion of equity across medical devices, pharmaceuticals, healthcare services and healthcare IT. Within the medical devices sub-sector, the Apax Healthcare team has partnered with a variety of businesses such as Mӧlnlycke, Vyaire Medical, Candela and Healthium to create strategic leaders in their space.

About Canada Pension Plan Investment Board
Canada Pension Plan Investment Board (CPPIB) is a professional investment management organization that invests the funds not needed by the Canada Pension Plan (CPP) to pay current benefits on behalf of 20 million contributors and beneficiaries. In order to build a diversified portfolio of CPP assets, CPPIB invests in public equities, private equities, real estate, infrastructure and fixed income instruments. Headquartered in Toronto, with offices in Hong Kong, London, Luxembourg, Mumbai, New York City, São Paulo and Sydney, CPPIB is governed and managed independently of the Canada Pension Plan and at arm’s length from governments. At December 31, 2018, the CPP Fund totalled C$368.5 billion.For more information about CPPIB, please visit www.cppib.com or follow us on LinkedInFacebook or Twitter.

About PSP Investments
The Public Sector Pension Investment Board (PSP Investments) is one of Canada’s largest pension investment managers with C$158.9 billion of net assets as of September 30, 2018. It manages a diversified global portfolio composed of investments in public financial markets, private equity, real estate, infrastructure, natural resources and private debt. Established in 1999, PSP Investments manages net contributions to the pension funds of the federal Public Service, the Canadian Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered in Ottawa, PSP Investments has its principal business office in Montréal and offices in New York, London and Hong Kong. For more information, visit investpsp.com or follow us on Twitter and LinkedIn.

###

Acelity Media Contacts:

Cheston Turbyfill,
VP, Corporate Communications Acelity
cheston.turbyfill@acelity.com
+1 312-952-0837

Acelity Investor Contacts:

David Clair, CFA,
Westwicke Partners
investors@acelity.com
+1-646-277-1266

Apax Partners: 

Global Media: Andrew Kenny, Apax | +44 20 7 872 6371 | andrew.kenny@apax.com
USA Media: Todd Fogarty, Kekst | +1 212-521 4854 | todd.fogarty@kekst.com
UK Media: Matthew Goodman, Greenbrook | +44 20 7952 2000 | apax@greenbrookpr.com

CPPIB:

Darryl Konynenbelt
Phone: +1 416-972-8389
Email: dkonynenbelt@cppib.com

PSP Investments:

Verena Garofalo
Phone: +1 (514) 218-3795
Email: media@investpsp.com

Search our news

Sector: All
Year: All

Global press contact

Andrew Kenny
t: +44 20 7872 6300
andrew.kenny@apax.comGreenbrook Communications
t: +44 20 7952 2000
apax@greenbrookpr.com

Kate Albert
t: +44 20 7872 6300
kate.albert@apax.com

See all Press contacts

Acelity

Leading provider of therapies and products for the advanced wound care, tissue regeneration and therapeutic support system markets

Categories: News

Tags:

Gimv’s Life Sciences team establishes Advisory Board. Industry veterans Darnaud, Hirth, Kola, Kutay, LeBeaut and Moses joining.

GIMV

29/04/2019 – 17:45 | Portfolio

Gimv announces it has created a Life Sciences Advisory Board. The new Advisory Board consists of 6 seasoned industry veterans with expertise in drug- and medtech development, company building and M&A. Michel Darnaud (former president cardiac surgery at LivaNova), Peter Hirth (former CEO Plexxikon), Ismail Kola (former CSO UCB), Kasim Kutay (CEO Novo Holdings), Alexandre LeBeaut (CSO Ipsen) and Edwin Moses (former CEO Ablynx) will assist the Gimv Life Sciences team with portfolio development, deal sourcing and assessing general industry trends.

Gimv has been active in Life Sciences since 1982, investing in more than 80 companies and generating a consistent top tier IRR. Successes include Ablynx, Plexxikon, Devgen, Covagen, Prosonix and Endosense. Embedded in the broader Health & Care platform, Gimv’s Life Sciences team is looking to invest in European early and late stage biotech and medtech companies in an amount of EUR 10-25 million per company, with funding coming from Gimv’s balance sheet in an evergreen setting. The Life Sciences team, including partners Karl Nägler, Bram Vanparys and Patrick Van Beneden, manages an active portfolio of 11 companies today and aims to expanding this to 15-20 companies over the coming years.

Karl Nägler: “Creating this advisory board highlights Gimv’s ambitions in the biotech and medtech field for the years to come. At Gimv we want to be partners for ambitious entrepreneurs. By establishing our Advisory Board we broaden the network and add value to our portfolio.”

Bram Vanparys adds “We are very happy to establish a close collaboration with these renowned and successful professionals, each of whom has done great things in our industry. With this collaboration, we can further increase Gimv’s value to patients, portfolio companies and shareholders.”

Categories: News

Tags:

Canopy Biosciences Acquires Zellkraftwerk GmbH

Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products and Services

ST. LOUIS — Canopy Biosciences™, LLC, a leading provider of gene editing and gene expression products and services, announced today that it has acquired Zellkraftwerk GmbH, a leader in multiplex cytometry. Leveraging its innovative ChipCytometry platform, Zellkraftwerk offers complete workflow solutions—including both products and research services—for high-content cytometry on cells and tissues. The combination of Canopy and Zelkraftwerk creates a unique “multi-omics” company that boasts a powerful union of genomics expertise with cutting-edge cell and tissue analysis solutions to best support customers in drug development research and biomarker discovery. Concurrent with the acquisition, Canopy closed a strategic growth investment from Ampersand Capital Partners.

Edward Weinstein, Ph.D., co-founder and CEO of Canopy Biosciences, said “I am excited to complete the transformational acquisition of Zellkraftwerk and begin our partnership with Ampersand. Ampersand’s expertise and resources will benefit Canopy as we build a broader product and service offering for our customers, and the Zellkraftwerk acquisition provides a meaningful contribution to this strategy.” Weinstein continued, “Zellkraftwerk founders Jan Detmers and Christian Hennig have built a truly differentiated offering within the cell and tissue analysis market, and we’re excited to add their unique expertise and technology platform to Canopy Biosciences.”

Cofounder of Zellkraftwerk, Jan Detmers added, “As the scientific community continues to appreciate the roles and relationships between genotypes, phenotypes, and the environment, the need for “multi-omic” approaches to biomarker discovery and functional biology research has never been clearer. We are excited to partner with Canopy Biosciences and Ampersand to enhance our capabilities, scale, and geographic reach in the US, Europe, and Asia as we strive to best serve the evolving needs of our customers.”

Frank Witney, Ph.D., Operating Partner at Ampersand and incoming Chairman of Canopy, said, “Ampersand invests in high quality teams who manage rapidly growing businesses with established leadership positions in their specific markets, and Canopy is a great example. We are thrilled to have the opportunity to partner with Ed and the rest of the Canopy management team as they expand their gene editing and genomics analysis portfolio in combination with Zellkraftwerk’s unprecedented multiplex cytometry technology.”

Canopy was formed in 2016 by BioGenerator, the funding arm of BioSTL in St. Louis, MO. Charlie Bolten, Senior Vice President of BioGenerator added “Canopy’s product portfolio is a result of a strategic approach to identify novel technologies and quickly commercialize products and services that will make an immediate impact on today’s biomedical research. BioGenerator is proud to have played a role in the founding of this company and is excited at Canopy’s continued growth prospects in partnership with Ampersand.”



About Canopy Biosciences

Canopy Biosciences was formed in 2016 and has rapidly built a comprehensive platform of products and services for gene editing, gene expression analysis and regulation, and bioprocessing. Canopy’s gene editing portfolio spans easy-to-use CRISPR kits, off-the-shelf cell lines, as well as full service custom cell line engineering. With the introduction of RareSeq, Canopy has added ultrasensitive DNA sequencing to its multi-omics platform including RNAseq, NanoString gene expression analysis, and multiplexed protein detection. Canopy Biosciences is headquartered in St. Louis, Missouri, and serves researchers at universities, research institutions and biotechnology and pharmaceutical companies worldwide. Additional information is available at www.canopybiosciences.com.

About Zellkraftwerk GmbH

Zellkraftwerk GmbH, with its headquarters in Leipzig, manufactures ZellScanner™ ONE, the first device able to analyze more than 100 markers per cell based on the Chipcytometry technology. The device allows for deep insights into formerly unknown cell subpopulations and their state of activation, while its microfluidic chips can be additionally used for sample storage that guarantee biomarker stability for up to 24 months. Zellkraftwerk works closely with top biopharma, diagnostics, and academic scientists performing preclinical and clinical research to enhance their capabilities in sample preparation, biobanking, multiplexed protein and biomarker analysis, and data mining. Additional information is available at www.zellkraftwerk.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Avista Pharma, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information is available at www.ampersandcapital.com.

About BioGenerator

BioGenerator, the investment arm of BioSTL, produces a sustained pipeline of successful bioscience companies and entrepreneurs in St. Louis by creating, growing and investing in promising new enterprises. Additional information is available at www.biogenerator.org.

***

Contact:
Kevin Gamber
kevin.gamber@canopybiosciences.com
314-662-9987

Categories: News

Tags:

Montagu Private Equity announces the completion of the sale of D.O.R.C.

Montagu

Montagu Private Equity (“Montagu”), a leading European private equity firm, today announced the completion of the sale of Dutch Ophthalmic Research Center (“D.O.R.C.” or “the Company”), a leading provider of innovative instruments and equipment for ophthalmic surgery, to Eurazeo Capital. Terms of the transaction are not being disclosed.

Established in 1983, D.O.R.C. is a leading provider of innovative instruments and equipment for ophthalmic surgery. The product range includes high precision disposable and re-usable instruments, surgical liquids and surgical machinery that is used for vitreoretinal and cataract procedures. Headquartered in Zuidland, the Netherlands, D.O.R.C. serves a global customer base including surgical centres, hospitals and physicians across the US, Europe, the mid-East, Asia and South America. The Company has more than 500 employees worldwide.

 

The transaction was first announced on 13 March 2019 and has now received clearance from relevant competition and regulatory authorities.

 

Montagu was advised by HSBC and RBC Capital Markets.

Categories: News

Tags:

EURAZEO CAPITAL completes its acquisition of DORC

Eurazeo

Paris, April 25, 2019 – Eurazeo Capital announces the completion of the acquisition of DORC (Dutch
Ophthalmic Research Center), one of the global leading specialists of vitreoretinal surgery. Headquartered
in the Netherlands, DORC designs, manufactures and distributes ophthalmic surgery equipment,
consumables and instruments worldwide. DORC enjoys strong market positions notably in Western
Europe, and more recently in the US.
DORC has a strong brand recognition and is widely recognized for its innovation track record. It has
delivered a consistently strong financial performance, supported by growing global ophthalmic surgery
needs.

In 2018, DORC generated revenues of €125 million, with an average annual growth rate of 9% over the
past 3 years. The transaction consists in the acquisition of 100% of the share capital of DORC and will be
the fifth investment of Eurazeo Capital IV. The company is valued at c. €430 million (enterprise value), of
which c. €300 million equity funded by Eurazeo and its affiliates.

About Eurazeo
o Eurazeo is a leading global investment company, with a diversified portfolio of €17 billion in assets under
management, including nearly €11 billion from third parties, invested in over 300 companies. With its considerable
private equity, venture capital, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies
of all sizes, supporting their development through the commitment of its 235 professionals and by offering deep sector
expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid
institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment
horizon enable Eurazeo to support its companies over the long term.
Eurazeo has offices in Paris, New York, Sao Paulo, Buenos Aires, Shanghai, London, Luxembourg, Frankfurt and
Madrid.
o Eurazeo is listed on Euronext Paris.
o ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

Categories: News

Tags:

ACTIVA CAPITAL acquires MEDISYS, software publisher in the medico-social sector, alongside entrepeneur Guillaume Bouillot

Activa Capital

Activa Capital has acquired a majority position in Medisys, together with Turenne Santé, the entrepreneur
and new CEO Guillaume Bouillot and the management team. Bernard Chevalier, founder, is supporting the
operation and remains a shareholder.
Medisys is a leading software publisher in the home-care field and for institutions specialized in dependent
persons.

After nearly 30 years at the head of the company based in Aix-en-Provence and created in 1991, its founder
Bernard Chevalier hands over the management to Guillaume Bouillot, a software entrepreneur.
The new management team will build on values that have made the company successful while providing
the means to accelerate the digitalization of personal services. The challenge is to support the
transformation of organizations that bring together care institutions, home support, medical/nursing
services and aids to daily life. Medisys’ development is based on its recognized expertise in the care of
dependent persons and on its technological innovations making it possible to streamline the operators’
organization and secure the patient follow-up. The company also intends to intensify the deployment of
traceability systems for hygiene and cleaning services in sensitive environments, particularly in the medical
sector, with its Mobiserv solution.
Thanks to 17 years of experience between the creation and sale of Eudonet (a publisher of CRM solutions),
Guillaume Bouillot brings a new energy to the company with a desire to accelerate by fostering links with
customers and the ecosystem.
Activa Capital and Turenne Santé will enable Medisys to strengthen its positions through strategic
acquisitions to complete its offer.

With this transaction, Activa Capital is making the 9th investment of its latest fund, Activa Capital Fund III.
Guillaume Bouillot, President of Medisys Holding, said: “I was very impressed by Activa Capital’s unique
ability to support entrepreneurs and bring its skills and energy to bear on their ambitions. The association
with the sector specialist Turenne Santé is a key asset for this transition from one entrepreneur to another
in a consolidating sector”.

Bernard Chevalier, Founder of Medisys, added: “This is a new momentum for Medisys, which has the solid
fundamentals to pursue and expand its rapid development and satisfy our most demanding clients in the
medico-social sector”.

Christophe Parier and Alexandre Masson, Partners of Activa Capital, completed: “We were impressed by
Medisys’ history and positioning. The arrival of Guillaume Bouillot will enable the company to carry out its
ambitious development projects. This acquisition is in line with Activa Capital’s strategy of investing in
companies that are at a turning point in their growth to help them accelerate their development”.

Mounia Chaoui, Associate Director, Turenne Santé stated: “We are delighted to support Guillaume Bouillot
and the Medisys teams in the takeover of the group, in partnership with Activa Capital. Medisys has
developed a remarkable offer that facilitates the development of home services, at the heart of new
healthcare policies that we are addressing with Capital Santé 2”.

Participants
New CEO
Corporate lawyer: Allen Overy (Raphaël Bloch)

Investors
Activa Capital: Christophe Parier, Alexandre Masson, Frédéric Singer, Elliot Thiéblin
Turenne Santé: Mounia Chaoui, Grégory Dupas
Financial Due Diligence: PwC (David Willems, Pierre-Mikhaël, Kévin Barrier)
Strategic Due Diligence: PMSI (Remi de Guilhermier, Florence Royer, Lucinda Nicholson)
Social and legal Due Diligence: Hogan Lovells (Stéphane Huten, Paul Leroy, Alexandre Jeannerot)
M&A advisor: Bryan Garnier (Thibaut De Smedt, Pierre Lafitte, Alexandre Brestin)
Corporate lawyers: Hogan Lovells (Stéphane Huten, Paul Leroy, Alexandre Jeannerot), Paul Hastings
(Sébastien Crepy)
Financing lawyer: Hogan Lovells (Alexander Premont, Luc Bontoux, Adrien Gaudron)

Founder
Vendor Due Diligence: Exelmans (Stéphane Dahan, Manuel Manas, Matthieu Réglade, Philippe Pelet)
M&A advisor: Edmond de Rothschild Corporate Finance (Philippe Duval, Marguerite Mell, Lucrèce
d’Assignies, Aurélien Rivière)
Corporate lawyer: Lamartine Conseil (Vincent Libaud)
Senior financing
Senior debt: Crédit du Nord (Bertrand Descours, Amandine Proux), Crédit Agricole Provence Alpes Côte
d’Azur (Christophe Lejeune, Violaine Mahier), BNP Paribas (Mathias Ronzeaud)

About Activa Capital
Activa Capital is an independent private equity company, owned by its partners, characterized by a proactive
strategy of supporting growth (organic and external). It currently manages more than €500 million on behalf
of institutional investors by investing in French SMEs and Mid-Caps with high growth potential and an
enterprise value ranging between €20 million and €100 million. Activa Capital supports its portfolio
companies to accelerate their development and international presence, often through active build-up
programs.
To learn more about Activa Capital, visit activacapital.com

About Turenne Capital Group
With more than €220 million under management, including more than €100 million for the FPCI Capital
Santé 2, Turenne Santé supports healthcare companies in their development and transmission challenges.

As an independent private equity player in France, the Turenne Capital group manages more than €1 billion.
Its teams, composed of 55 professionals, including 38 investors, based in Paris, Lille, Lyon, Marseille and
Metz, support more than 250 companies employing more than 23,000 people in the health, hospitality,
new technology, distribution and innovative services sectors.
To learn more about Turenne Capital, visit www.turennecapital.com

Press contacts
Christophe Parier Alexandre Masson Christelle Piatto
Partner Partner Communications Manager
+33 1 43 12 50 12 +33 1 43 12 50 12 +33 1 43 12 50 12
christophe.parier@activacapital.com alexandre.masson@activacapital.com christelle.piatto@activacapital.com
Mounia Chaoui Josepha Montana
Partner Communications Manager
+33 1 53 43 03 03 +33 1 53 43 03 03
mchaoui@turennecapital.com jmontana@turennecapital.com

Everstone Group to acquire controlling stake in Sahyadri Hospitals

Everstone

Mumbai, April 07, 2019 – The Everstone Group(Everstone), has signed an agreement to acquire a controlling stake in Sahyadri Hospitals Limited(Sahyadri), the largest hospital chain in Maharashtra. The combination of primary and secondary capital outlay is expected to increase the bed-count significantly in next five years.

Founded in 1994, Pune headquartered Sahyadri Hospitals currently operates 5 tertiary care and 3 secondary care hospitals with 750 beds across Pune (Deccan Gymkhana, Nagar Road, Kothrud, Bibwewadi, Kasba Peth and Hadapsar), Nashik and Karad areas. Sahyadri has more than 1000 clinicians along with 2300 supporting staff providing latest medical services.

Sameer Sain, CEO, Everstone Group, said, “Sahyadri Hospitals is a reputed name for quality healthcare and will act as the anchor asset of our healthcare delivery platform. Everstone will leverage its’ significant healthcare expertise and experience to grow the overall business. We look forward to working closely with our partners and stakeholders.”

Commenting on the investment, Dr. Charudutt Apte, Founder, Chairman and MD, Sahyadri Hospitals said, “We are excited about this partnership and the value Everstone Group brings. Sahyadri Hospitals looks forward to the next phase of growth with the support of the experienced team at Everstone.”

According to industry estimates, private secondary and tertiary healthcare delivery in India is expected to grow from USD 42 bn in 2018 to USD 65 bn by 2022 at a CAGR of ~12%. This investment will help Sahyadri to cement its position as the leading healthcare chain in Maharashtra.

Everstone is one of the largest India and South East Asia focused healthcare investor specializing in rolling up assets within their platforms. In 2015, Everstone successfully exited Global Hospitals, a large multi-specialty tertiary hospital chain, generating strong returns. Everstone’s healthcare portfolio includes controlling stakes in domestic pharma distribution platform, Ascent Health; South East Asia based diagnostic device platform Everlife and an investment in one of the largest nutraceutical ingredient business, OmniActive. Everstone recently announced its successful exit from Rubicon Research (Rubicon) generating returns of 4.5x.

About Everstone Group
Everstone is a premier investment group focused on India and South East Asia, with assets in excess of US$5 billion across private equity, real estate, green infrastructure and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India (Mumbai, Delhi, Bangalore), London, New York and Mauritius, comprising best-of-breed investing, operations and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com
LinkedIn

About Sahyadri Hospitals
Sahyadri Hospitals is the largest chain of hospitals in Maharashtra with 8 hospitals across three cities of Pune, Nashik and Karad. The hospital chain has over 900 Beds, 1,200 Clinicians and 2,300 Support Staff providing round the clock healthcare.
To know more: www.sahyadrihospital.com

Categories: News

Tags:

Carlyle Cardinal Ireland Invests in Sports Surgery Clinic

Carlyle

Specialist Orthopaedic & Sports Medicine Hospital To Focus on Continued Growth of Patient Services and Facilities

Dublin, Ireland – Carlyle Cardinal Ireland (CCI), the private equity fund established by The Carlyle Group (NASDAQ: CG) and Cardinal Capital Group, has agreed to an investment in Sports Surgery Clinic (SSC), a private hospital specialising in orthopaedic surgery, spinal surgery and sports medicine.  The investment, terms of which are not being disclosed, is expected to complete in the coming months.

SSC, located in Santry, Dublin, is a state-of-the-art private hospital dedicated to orthopaedics and sports medicines.  Launched in 2007, SSC introduced world-class facilities and treatment into Ireland for orthopaedic joint-replacement surgery, spinal surgery and sports medicine.  The hospital has quickly grown to become a premier provider of both sports medicine and orthopaedic joint-replacement surgery in Ireland with a reputation for leading-edge innovation and highest standards of patient care.

Facilities at SSC include five ultra-clean-air operating theatres dedicated to orthopaedic and spinal surgical procedures, a diagnostic-imaging service including two 3-Tesla MRI scanners and a 64-slice CT scanner, and an expansive physiotherapy and rehabilitation department incorporating wellness and health-screening facilities.  A recently developed sports medicine-dedicated laboratory provides performance rehabilitation, running clinics, fitness testing and physiotherapy services.  Currently employing over 300 people, SSC’s capacity comprises 63 in-patient beds, 26 day-care beds and 21 on-site consultancy suites.

Jonathan Cosgrave, Managing Director, The Carlyle Group and John Dolan, Managing Director, Cardinal Capital Group, will join the board of directors of SSC upon completion of the investment.

Dr. Josh Keaveny, Chief Executive, SSC said: “With our patient-focused model of care we are continuously exploring the science and medicine related to sports injuries, athletic performance, joint replacement and spinal injury.  We aim to keep people of all ages fit and active.  The investment from CCI allows us to accelerate our growth and we plan to begin work in the near future on expanding the hospital.  This expansion will significantly increase our capacity which will enable us to treat more patients.”

John Dolan, Managing Director, Cardinal Capital Group, said: “CCI’s financial backing of SSC’s expansion plan will add two additional theatres, which will increase surgical capacity by 40%, meaning more of the population can readily access the hospital’s leading facilities and consultants.  With an increased focus on exercise and wellness, more and more people are looking for restorative procedures, particularly knee and hip replacements, and shoulder surgery.  SSC’s specialist orthopaedic and rehabilitation expertise has allowed it establish a national reputation for treating injuries in both professional and amateur athletes, and members of the wider population.”

Jonathan Cosgrave, Managing Director, The Carlyle Group, said: “SSC is CCI’s second healthcare sector investment and we are excited to be partnering with such a high quality, ambitious management team and group of staff.  Planned increases to SSC’s operating capacity will expand SSC’s workforce and we look forward to adding new consultants, nurses and other healthcare professionals to the SSC team.  The Irish population aged over 65 years is forecast to increase 45% by 2030 driving a significant increase in annual demand for hip and knee joint replacements, and SSC’s management team and staff are well positioned to service this growing patient demand.”

CCI has been an active growth investor in the Irish market since 2014.  SSC is the fund’s tenth investment and the fund continues to explore other investment opportunities.  Current fund investments include The AA Ireland, Payzone, Carroll Cuisine, Learning Pool, McCauley Pharmacy Group, Abtran and Millicent Pharma.  CCI previously invested in Lily O’Brien’s and General Secure Logistics Services (GSLS), both high-growth companies run by first-class management teams, each of which underwent an exit process in 2018.

CCI’s investment in SSC is subject to approval from the Competition and Consumer Protection Commission (CCPC).

* * * * *

Press Contacts:

The Carlyle Group
Laurie Mannix, MKC Communications
Tel: +353 (0)1 703 8620 Mob: +353 (0)86 814 3710 laurie@mkc.ie

Cardinal Capital Group
Tom McEnaney, McEnaney Media
Tel: +353 (0)87 2222 666 tom@tommcenaney.com

About Sports Surgery Clinic (SSC)

SSC’s goal is dedicated to delivering the highest standards of diagnosis, prehabilitation, treatment, rehabilitation and full recovery care for its patients.  The hospital aims to provide an exceptional working environment for staff with a focus on continuous education and quality improvement to support excellence in patient care.

SSC’s facilities are built with optimised patient outcomes in mind.  They include five ultra clean-air operating theatres, a world-class diagnostic imaging department, an expansive physiotherapy department, a wellness and health screening facility, as well as dedicated research laboratories which highlight the commitment that SSC places on promoting future breakthroughs in orthopaedic surgery.

SSC offers patients all the advantages of the newest technologies, including 21 on-site consulting rooms that ensure rapid and smooth access to consultant expertise on a continuous basis.  The hospital houses some of the world’s most advanced radiology equipment including two 3-Tesla MRI scanners and a 64-slice CT scanner, both of which yield superior image quality and resolution, particularly in the diagnosis of soft tissue and orthopaedic injuries.

Patient comfort is at the heart of the service provided by the SSC.  In total, the clinic offers 63 in-patient beds in addition to 26 day-care beds.  Each patient room has its own ensuite bathroom with shower, and entertainment centre incorporating internet, radio and telephone access along with both clinic and treatment information.

About Carlyle Cardinal Ireland

Carlyle Cardinal Ireland is a joint venture between The Carlyle Group (NASDAQ: CG) and Cardinal Capital Group.  The €292 million private equity fund is focused on growth capital and buyout investment opportunities across the island of Ireland.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $216 billion of assets under management as of December 31, 2018, Carlyle’s purpose is to invest wisely and create value on behalf of our investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,650 people in 31 offices across six continents.

The Carlyle Group is a seasoned investor in the hospital sector.  Notable hospital investments include Schoen Klinik (Germany  17 hospitals), Rede D’Or São Luiz (Brazil  38 hospitals), Healthscope (Australia  45 hospitals), Medical Park (Turkey – 18 hospitals) and Medanta (India  3 hospitals, 1 Day Care Facility and 2 new hospitals under construction).

Web: www.carlyle.com
Videos: www.youtube.com/onecarlyle
Tweets: www.twitter.com/onecarlyle
Podcasts: www.carlyle.com/about-carlyle/market-commentary

About Cardinal Capital Group

Cardinal Capital Group is Ireland’s leading provider of alternative capital, directing private-equity capital, mezzanine finance and alternative lending to a broad range of sectors in the Irish market.  Cardinal invests its own capital alongside institutional funders to support entrepreneurs and corporate management teams as well as real-estate investors and developers.

Web: www.cardinalcapitalgroup.com

Categories: News

Tags: